Biogen to pay $1.25B settlement in multiple sclerosis drug case
January 17, 2017 at 08:59 AM EST
The giant settlement and licensing agreement could help Cambridge biotech Biogen extend the life of its multiple sclerosis drug, Tecfidera, which accounts for around a third of its total revenue.
